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INTRODUCTION
The integration of modern genetics, biochemistry, and mo-
lecular biology techniques into the field of virology over the
last 30 years has led to quantum leaps in our understanding of
the molecular mechanisms by which different virus infections
cause novel pathogenic disease outcomes. The ability to ana-
lyze the effects of each viral protein on the host transcriptome
and proteome coupled with the ability to identify the interac-
tion partners that impact host cell signaling pathways is en-
abling the current generation of scientists to interrogate host-
pathogen interactions at the molecular level, developing a
system-wide view of disease processes. The use of viral reverse
genetic systems for model viruses and gene knockout mice
allows virologists to investigate the detailed interactions that
occur during infection to regulate complex disease outcomes.
Our understanding of coronavirus pathogenesis, especially that
of mouse hepatitis virus and severe acute respiratory syndrome
coronavirus (SARS-CoV), has increased exponentially since
the creation of reverse genetic clones for each virus in recent
years (2, 159, 160).
Using this growing suite of new molecular tools, our labo-
ratory and others have been investigating the interactions be-
tween the virus and host during the initial phases of disease.
The initial host response to infection is controlled by the innate
immune system, a complex, highly regulated network of cyto-
kines, chemokines, complement proteins, macrophages, and
dendritic cells (DCs), which serves as a robust barrier to the
establishment and maintenance of a productive virus infection.
However, viruses have coevolved an armament of components
that evade and/or block host innate immune responses, or they
express components that shield infection from detection (3, 5,
22, 35, 81, 92, 93, 127, 151, 156). Given the diverse array of
novel genetic functions, it is not surprising that coronaviruses
also encode several proteins that modulate the host innate
immune response during infection.
HUMAN CORONAVIRUSES AND DISEASE
Classically, human coronaviruses 229E and OC43 were
viewed as causing mild upper respiratory tract infections.
Moreover, animal models of disease were lacking, sparking
minimal interest in identifying the determinants that regulate
disease outcomes. OC43 has been found throughout the world
to be a cause of both the common cold and other more severe
respiratory diseases, especially in children and the elderly (8,
30, 137). More recently, Patrick et al. found that in an elder
care facility, almost 50% of staff and patients were OC43 pos-
itive during an outbreak of severe respiratory disease. Infected
elderly patients showed severe respiratory distress and pulmo-
nary symptoms, resulting in a 10% mortality rate (94). Human
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coronavirus 229E has also been found to cause lower respira-
tory tract disease, mostly in the elderly, infants, and individuals
with chronic underlying immune conditions (6). These new
revelations, coupled with the emergence of the highly patho-
genic SARS-CoV, demonstrated that coronavirus genomes
likely encode unusual determinants that promote severe dis-
ease outcomes, especially in the elderly. The advent of SARS-
CoV resulted in the identification of two new human corona-
viruses, NL63 and HKU1, which produce severe lower
respiratory tract infections in infants and young children and in
aged adults, respectively (100, 150). In particular, the first
report of HKU1 infection was initially documented as being a
SARS-CoV case in an elderly Hong Kong patient (150). The
growing recognition that human coronaviruses are important
and potentially highly pathogenic has revitalized interest in
understanding pathogenic pathways to disease as well as the
development of vaccines and therapeutics for controlling and
preventing severe disease outcomes. Among the human coro-
naviruses, SARS-CoV is the best characterized both biochem-
ically and molecularly (146), displays robust growth in primary
and continuous cell lines, has well-characterized young and/or
aged animal models of human disease (106–108, 147), and has
well-documented reverse genetic approaches (2, 160), and vac-
cine efficacy has been studied in young and aged animal models
(26, 155). Importantly, the first coronavirus antagonists of in-
nate immunity were documented in the SARS-CoV genome
(59), pioneering similar studies in other important human and
animal CoV genomes (156).
CORONAVIRUS VIRION AND GENOME ORGANIZATION
The coronavirus genome is about 30 kb in size and generally
encodes three broad protein classes (76, 112) (Fig. 1). Virions
are roughly 90 to 120 nm in diameter and contain a lipid
bilayer surrounding a helical nucleocapsid structure that pro-
tects the genome. Several structural proteins are encoded
within the intact virion, and these include the 180/90-kDa spike
(S) protein, a 50- to 60-kDa nucleocapsid (N) protein, an
8-kDa envelope (E) protein, and the 23-kDa membrane (M)
protein. A second class of genes encodes the accessory or
group-specific proteins. These proteins are typically unique to
each particular coronavirus strain and differ among MHV,
SARS-CoV, and the other human coronaviruses. In the case of
SARS-CoV, ORF3a, ORF6, and ORF7a/b are reported virion
proteins (49, 117, 121), although the literature lacks consensus
(86). The exact functions for most of these proteins are un-
clear; however, these proteins may influence viral pathogenesis
and disease outcomes, regulate specific virus-host interactions,
and/or promote the development of an intracellular environ-
ment that is conducive for efficient virus growth. In many but
not all cases, the deletion of the group-specific open reading
frames (ORFs) has a minimal impact on in vitro replication but
may or may not attenuate pathogenesis in vivo, depending on
the virus strain (24).
The final broad category of coronavirus genes encodes the
replicase proteins, also called nonstructural proteins. These
viral proteins are encoded in the 5-most two-thirds of the
coronavirus genome, which is essential for polyprotein process-
ing, replicase complex formation, and efficient virus replication
(9). More recently, it is becoming clear that the replicase pro-
teins may also encode critical virulence determinants that not
only regulate virus growth efficiency but also directly engage
the host proteome to directly potentiate pathogenic mecha-
nisms and regulate disease severity (27, 170).
INNATE IMMUNE INDUCTION
The innate immune response is a coordinated series of sig-
naling pathways in all nucleated cells that function to thwart an
invading pathogen’s replication and disease potential. From
interferon (IFN) induction and secretion to the recruitment of
macrophages and DCs to sites of infection, the system func-
tions to restrict tissue tropism and spread, dampen virus rep-
lication efficiency, and eliminate virally infected cells (reviewed
in references 36, 119, and 133). In addition to IFN regulatory
factor 3 (IRF3) in the IFN pathway, another critical signaling
protein for the innate immune response is nuclear factor of
kappa light polypeptide gene enhancer in B cells (NF-B).
NF-B is activated during viral infection from the sensing of
viral replication products and via cytokine secretion from mac-
rophages and DCs (37). This leads to a broad induction of the
innate immune response while also fine-tuning the response to
remove virus while not harming the cells.
The modulation of these pathways is critical for virus sur-
vival, as evidenced by the many viruses that express proteins
that block various key effector proteins in these pathways and
from the increased disease severity noted in many gene knock-
out animals. Protein products from many viruses including the
FIG. 1. SARS-CoV and MHV genome structure. The genome structure of coronaviruses is very conserved among all known coronaviruses. In
each coronavirus, the N-terminal two-thirds of the genome encodes the nonstructural proteins, also called the replicase proteins (orange box). The
C-terminal one-third of the genome encodes the structural (red boxes) and accessory (gray boxes) ORFs. The structural ORFs encode the spike,
envelope (E), membrane (M), and nucleocapsid (N) proteins. Each coronavirus has similar structural ORFs in their genomes. The accessory ORFs,
in gray, are unique to each coronavirus. There is no sequence or structural similarities between the MHV and SARS-CoV accessory proteins.
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NSP1, ORF6, and N proteins from SARS-CoV (34, 56, 59, 84,
144, 156), the NS1 protein from influenza virus (114, 164), the
VP35 and VP24 proteins from Ebola virus (5, 104), the leader
protein from picornaviruses (25, 42, 138), and the V proteins
from Nipah and Hendra viruses (3, 111) have each been iden-
tified as being immunomodulating proteins. Each protein
blocks one or more key signaling proteins in the IFN and
NF-B pathways to enhance viral replication and pathogenesis.
The influenza virus NS1 protein affects the IRF3 signaling
pathway as well as mRNA stability and trafficking (60, 164). In
contrast, VP35 from Ebola virus and ORF6 from SARS-CoV
block nuclear import (34, 59), while the V proteins from Nipah
and Hendra viruses induce signal transducer and activator of
transcription (STAT) protein degradation (111). Picornavirus
leader blocks by binding to promoter regions of IFN genes via
a zinc finger domain and inhibits transcription (25, 42, 138).
Each protein antagonizes the innate immune response but uses
different tools and targets to achieve these goals. An under-
standing of how each antagonist affects the innate immune
response illuminates key interactions between the host signal-
ing pathway components and the virus. In addition, these stud-
ies pinpoint key host cell components that function to regulate
virus replication and pathogenesis, providing novel targets for
the development of antiviral compounds.
Interferon
Initially identified as a protein that interfered with virus
replication by Isaacs and Lindenmann in 1957, IFNs are key
regulators of viral replication in mammals and birds (52, 125,
128). Recently, several new types of IFN have been identified,
adding to the previously known type I IFNs (alpha and beta),
type II IFN (gamma), and now type III IFN (lambda) (4, 58,
136) (Table 1). The lesser known omega IFN (IFN-), IFN-,
and IFN- are part of the type I IFN family (7, 67, 77, 122,
148), although the role of these new and lesser-studied IFNs in
coronavirus replication and pathogenesis is unknown.
The induction of IFN by various cell types is an initial signal
to the host that a foreign invader has infected its cells. The
production of IFN by cells induces neighboring cells to re-
model the intracellular environment by producing a range of
antiviral proteins, aiding in a block of viral replication (115).
Several hundred proteins are induced following IFN produc-
tion and signaling (125). The mechanism of how these IFN-
induced proteins block virus infection is mostly unknown, but
some well-studied players include the RNA-dependent protein
kinase (PKR), RNase L, the Mx gene product, and the IFN-
stimulated gene 15 (ISG15) protein (45). Different IFNs in-
duce different genes both quantitatively and qualitatively in
cell culture. For example, IFN- and IFN-	 (also called inter-
leukin-28 [IL-28]) use the same signaling pathway to induce
ISGs, although they induce distinct but overlapping sets of
genes at different time points after stimulation (58, 136). How
the architecture of the signaling pathways regulates differential
gene expression is unknown, especially in cell types derived
from different tissues, and represents a major unresolved ques-
tion in the regulation of the antiviral response (75). Some ISGs
have been shown to affect coronavirus replication and will be
discussed below in more detail. IFN induction is known to
occur from any nucleated cell, although the type and amount
of IFN produced vary with the cell type (19).
Interferon Induction
There are several pathways by which virus infection and IFN
alter host gene expression patterns in the cell (Fig. 2). The
most direct pathway is via the presence of viral double-
stranded RNA (dsRNA) in the cell. Two dsRNA-sensing mol-
ecules, RIG-I and MDA5, reside in the cytoplasm of nucleated
cells and are able to discern viral dsRNA from host dsRNA
(57, 169). The mechanism of discrimination is thought to be
regulated by the recognition of the 5 cap on the mRNA by
RIG-I, while MDA5 may recognize uncapped mRNAs that are
often produced during the replication of some viruses. Host
mRNA is always capped and thus invisible to the dsRNA-
sensing machinery (97). There is new evidence that different
viruses activate each sensor uniquely, although the details of
the recognition and activation processes are still under study
(46, 70, 73, 97, 129). Once one or both of these sensors are
activated, they interact with a mitochondrial membrane pro-
tein called MAVS (mitochondrial antiviral) (also called IPS1,
Cardif, and VISA) (73, 97, 129). MAVS function is dependent
on mitochondrial localization; however, the reason for that
dependence is unknown (46, 70). Once MAVS becomes acti-
vated, the signaling cascade continues through the kinases
TBK1 and IKKε (reviewed in reference 118). IKKε signaling
has also been shown to induce many IFN-inducible proteins via
the STAT1 pathway as well (132). These kinases integrate the
upstream signaling events and then directly phosphorylate the
transcription factor IRF3, which normally resides in the cyto-
plasm. IRF3 phosphorylation promotes dimerization, and the
IRF3 dimer is imported into the nucleus by a karyopherin
(importin) complex where, with the help of other transcription
factors like NF-B, the complex initiates the transcription of
IFN-
. The IFN-
 protein is then secreted from the cell and
can act in either an autocrine or a paracrine fashion to amplify
the IFN response (125).
On the surface of most nucleated cells, the type I IFN re-
ceptor functions to detect and bind IFN- and -
 and initiate
the IFN signal transduction pathway (Fig. 3). This pathway
begins with the recruitment of kinases (JAK1 and TYK2) to
the cytoplasmic tail of the activated receptor. Once activated,
these kinases phosphorylate the cytoplasmic STAT proteins.
When IFN-
 is the inducer, STAT1 and STAT2 are phosphor-
ylated, leading to the formation of the ISGF3 complex, con-
sisting of STAT1, STAT2, and IRF9. This complex, now active,
is imported into the nucleus via the karyopherin alpha 1
(KPNA1)/karyopherin beta 1 (KPNB1) proteins (80). Once in
TABLE 1. Types of IFN identified
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the nucleus, RAN-GTP is hydrolyzed in the karyopherin com-
plex, and the cargo is released. In the nucleus, ISGF3 induces
the expression of several hundred genes, the promoters of
which all contain a specific element, the IFN-stimulated re-
sponse element (ISRE). The many genes induced in response
to IFN-
 prime the cell to block the replication of the virus.
This may affect either the cells already infected or neighboring
cells, which bind and induce antiviral proteins in response to
secreted IFN (68).
TLR Signaling
The Toll-like receptor (TLR) sensors also function as a
major pathway for the induction of IFN. The TLR family is
composed of 13 related paralogs in the human genome, each
with overlapping but distinct binding and signaling potentials.
From single-stranded RNA, dsRNA, CpG DNA, bacterial, and
viral protein components, the TLRs signal the cell to activate
various antipathogen defenses (133). Viral sensing is mediated
primarily via recognition patterns encrypted in TLRs 3, 7, 8,
and 9 (1). TLRs are membrane-spanning proteins and recog-
nize pathogen-associated molecular patterns (1). Pathogen-
associated molecular patterns are small structures and motifs
common to viruses or bacteria, such as lipopolysaccharides,
dsRNA, or unmethylated CpG DNA. The key to their recog-
nition is that TLRs reside in the endosomal membrane, with
their receptor ends facing the lumen of the vesicles, which
FIG. 3. The JAK/STAT signaling pathway and SARS-CoV. The
JAK/STAT pathway responds to type I IFN secreted from neighboring
cells. The IFN-/
 receptor binds to either IFN- or -
 and signals to
the Jak1 or TYK1 kinase. These kinases phosphorylate both STAT1
and STAT2. This phosphorylation induces the complex formation of
STAT1/STAT2/IRF9 (the ISGF3 complex) and targets the complex to
the nucleus with the help of the import factors KPNA1 (K1) and
KPNB1 (K
1). Once in the nucleus, the complex turns on genes
containing an ISRE in their promoter. SARS-CoV proteins have been
shown to affect this pathway. NSP1 reduces the levels of Jak1 in the
cytoplasm and affects it kinase activity. ORF6 blocks the nuclear im-
port of ISGF3 by reducing the free K
1 in the cytoplasm and retaining





















FIG. 2. The innate immune induction pathway and SARS-CoV. The major proteins in the innate induction pathway are shown as they signal
from sensing a pathogen to induction of IFN-
. Initially, RIG-I and MDA5 sense dsRNA in the cytoplasm, produced as a by-product of RNA virus
replication. They signal to the mitochondrial membrane protein MAVS, which in turn activates the kinases TBK1 and IKKε. These kinases then
phosphorylate IRF3, causing it to dimerize and traffic to the nucleus, where it, along with NF-B, induces the transcription of IFN-
. SARS-CoV
proteins actively modulate this pathway. ORF3b, N, and NSP1 affect the signal transduction pathway that activates IRF3 by an unknown
mechanism. NSP1 also affects the mRNA stability of IFN-
 transcript. The PLP of SARS-CoV also affects IRF3 and NF-B. PLP blocks the
phosphorylation of IRF3 and its activation while also blocking the activation of NF-B. This results in a block in IFN-
 induction.
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allows the proteins to sense the incoming virus after it is en-
docytosed into the cell. TLRs, which use different adapter
proteins, in comparison to RIGI and MDA5, use the scaffold-
ing proteins TRIF and MyD88 to signal through MAVS and
IRF3 before inducing the expression of IFN. Cervantes-Bar-
rangan et al. demonstrated that TLR7 is critical for IFN in-
duction in plasmacytoid DCs (pDCs) when infected with MHV
(12). These pathways may work in concert or independently to
induce IFN expression and establish the antiviral response.
Continued investigations into the similarities and differences of
TLR interactions with SARS-CoV and other coronaviruses
will be beneficial for understanding their role in coronavirus
pathogenesis.
Innate Immune Response and Coronaviruses
SARS-CoV and MHV, both group II coronaviruses, have
been shown to interact intimately with the innate immune
response. As reported for other viruses, the coronavirus-host
interplay and response outcome are highly dependent on cell
type, virus concentration, and whether the results are obtained
from in vitro or in vivo experimentations. MHV and SARS-
CoV induce various degrees of IFN as well, depending on all of
these variables (139, 168); type I IFN expression was found to
be induced following SARS-CoV infection of macrophages
(157), DCs (66), and epithelial cell lines (Caco2, MA104, and
293) (90) as well as in vivo in mice, macaques, and humans (38,
106, 141). Various degrees of induction have been found in
these cell lines, from very high early levels that diminish during
infection, to very high levels only late in infection, to no in-
duction of IFN at all. The reasons behind these differences are
currently not well understood.
The interaction between SARS-CoV and the innate immune
system appears to be tightly balanced during infection. In mac-
rophages and DCs, SARS-CoV has been shown to induce type
I IFN mRNA production (11, 123); however, the extent of
induction and the number of cells inducing IFN were not
analyzed. From these experiments, it is unclear whether the
virus is actually entering the cells or just binding signaling
molecules on the surface. Additionally, several groups have
performed microarrays on infected cells, and despite finding
little, if any, type I IFN mRNA expression, they noted a sig-
nificant induction of many downstream cytokines and chemo-
kine genes that were normally induced after the induction of
type I IFN (18). Although it is currently unclear which signal-
ing pathways are most responsible for protection from SARS-
CoV pathogenesis, these data illustrate the complexity and
wealth of undiscovered signaling networks in this area.
SARS-CoV AND HUMAN INFECTIONS
During and after the SARS epidemic in 2003, patient sam-
ples were analyzed to determine the molecular basis for viral
pathogenesis in humans. Using these samples, the age of the
patient was shown to dramatically influence disease outcome
and host cytokine responses following infection. For example,
levels of IFN-, IL-4, and IL-10 were increased only in conva-
lescent SARS-CoV patients, while IL-6 was upregulated in
most SARS-CoV patients (167). There was a correlation be-
tween the expression of the cytokines IL-6, IL-8, and monocyte
chemoattractant protein 1 and IP-10 with higher mortality and
severity of disease (103).
In those same studies, microarray-based quantification of
cytokine transcripts was performed using peripheral blood
mononuclear cells from infected patients. Increased levels of
proinflammatory cytokines were seen across all infected pa-
tients, but interestingly, little IFN- or -
 was found. This may
be due to the stability of the transcripts in the infected cells, or
it may be due to the IFN-antagonistic differences in SARS-
CoV-infected cells. It is unknown how cytokine induction dur-
ing infection is modified by SARS-CoV and how this relates to
the pathogenesis of the virus. Analyses of human samples have
identified markers of severity such as human leukocyte antigen
class I (B*0703) and class II (DRB1*0301), mannose binding
protein, OAS1, and MxA (43, 87, 163, 165). Reproduction of
these findings has been difficult due to small sample sizes and
limitations of access of the samples (153, 163). More recently,
IL-12 RB1, Rantes, and IFN- polymorphisms were linked to
SARS disease severity (16, 88). Undoubtedly, more genomic
links to disease will be found in the future.
IFN Evasion Mechanisms
Targeted gene knockout studies have demonstrated the crit-
ical importance of the innate immune system in regulating
virus-induced disease outcomes. Consequently, it is very likely
that this network of host genes has exerted considerable pres-
sure to select for coevolutionary changes in viral gene function.
One way that viruses have evolved to combat the innate im-
mune system is to encode protein functions that block various
aspects of the host response to viral infection. SARS-CoV and
MHV have been shown to produce large amounts of IFN-
inducing dsRNA while not inducing IFN in those cells (139,
145). Although mechanistically unclear, several possibilities
are under investigation. The viruses may be encoding proteins
(IFN antagonists) that directly inhibit the signaling pathways
that are responsible for IFN induction, as described above.
Significant amounts of data support the hypothesis that coro-
naviruses encode one or more IFN antagonist genes. The virus
may also be able to evade detection by replicating in privileged
sites that are compartmentalized from the sensing and signal-
ing machinery. For example, coronaviruses have been shown to
replicate on double-membrane vesicles which may protect the
viral RNA from sensing (98, 126). One hypothesis is that dou-
ble-membrane vesicles protect the dsRNA by internalizing the
RNA into the vesicle, while others hypothesized that the viral
replication machinery somehow binds and protects this RNA.
In support of this hypothesis, when cells are infected with
either MHV or SARS-CoV, there is no induction of IFN-
.
However, when superinfected with Sendai virus or treated with
poly(I:C), after the initial coronavirus infection, there is sub-
stantial IFN-
 induction (33, 168). When MHV was used to
infect conventional DCs in vitro (12), low levels of type I IFN
mRNA were reported. Similarly low levels of type I IFN were
found in the brains of infected mice in vivo (105). Spiegel and
Weber showed that in SARS-CoV-infected Caco2 and HEK
293 cells, little, if any, IFN-, -
, or -	 was induced (124).
Interestingly, IP-10 and IL-8 were also strongly induced in
Caco2 cells but not HEK 293 cells. The difference in cytokine
induction between these two cell lines is not understood but
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may be important for the underlying differences seen in hu-
mans and mice as well. These data suggest that one or more
pathways inhibited by coronavirus infection can still be acti-
vated by other inducers or that when tested in cell culture
models, the blocking of IFN signaling pathways is incomplete.
Continued studies of the location and dynamics of replicating
and translated viral RNA in the cell will aid in understanding
this phenomenon.
Structural Proteins
Coronavirus virions are made up of several virally encoded
proteins including the spike, envelope, membrane, and nucleo-
capsid proteins. The spike (S) protein is a heavily glycosylated
type I membrane protein that decorates the outside of the
virion and is essential for attachment to the host receptor. For
SARS-CoV, angiotensin-converting enzyme 2 (ACE2) (69) is
the receptor. For MHV, the receptor is Ceacam1 (carcinoem-
bryonic antigen-related cell adhesion molecule 1) (149). Im-
portantly, the S glycoprotein has been shown to affect several
cell signaling pathways in vitro. Using overexpression plasmids
in HeLa cells, the S glycoprotein was proposed to inhibit host
cell translation by interaction with eIF3f (152). In addition, S
glycoprotein induces apoptosis in VeroE6 cells (17), stimulates
macrophages to produce proinflammatory cytokines (IL-6 and
tumor necrosis factor alpha) in Raw 264.7 cells (143), and
activates COX-2 expression in VeroE6, HEK 293, and Cos7
cells (72). Spike has also been shown to downregulate ACE2
on the surface of cells. After binding on the surface, both
ACE2 and the virion are internalized (63), potentially reducing
the amount of ACE2 on the surface and preventing the cleav-
age of ACE. Importantly, ACE is a proinflammatory molecule
that normally functions in wound repair and healing of acute
lung injury (62). After SARS-CoV infection, the amount of
ACE2 on the surface of cells is reduced via internalization with
the SARS-CoV virion (51). This reduces the level of signaling
that ACE would normally induce when bound to cells and
slows the repair process, potentially exacerbating the lung
pathogenesis of SARS-CoV (62).
A correlation with ACE2 binding/internalization and patho-
genesis has recently been demonstrated for SARS-CoV. Rockx
et al. and Sheahan et al. were able generate viruses that con-
tain the Urbani genetic backbone but that have different zoo-
notic or human strain spike glycoproteins. Their spike se-
quences were based on the evolutionary changes that occurred
during animal-to-human SARS-CoV cross-species transmis-
sion and adaptation to the human host (110, 120). Those au-
thors showed that while different spike proteins can utilize the
same ACE2 receptor for efficient entry, different spike proteins
cause various levels of pathology in the lung, especially in aged
rodent models. They hypothesized that not only are the bind-
ing and internalization of ACE2 an important aspect of SARS-
CoV pathogenesis, but the modulation of the ACE2 signaling
network is critical for the acute lung injury seen in survivors of
SARS-CoV infection.
The envelope (E) protein is a small transmembrane protein
that is expressed abundantly but incorporated in small quan-
tities into the virion. In cells, it was proposed to coordinate
with the M glycoprotein to regulate efficient budding via direct
or indirect interactions with the nucleocapsid (9). The E pro-
tein has also been shown to form ion channel-like pores on
membranes in infected cells, but the role of the pores in patho-
genesis is unknown (135). While essential for group I corona-
virus virion formation, the E protein can be deleted from group
II coronaviruses like SARS-CoV and MHV, curtailing efficient
assembly, release, and pathogenesis in vivo, presumably by
limiting virus titers and the rate of spread (32, 65). Consonant
with these findings, recombinant SARS-CoVs lacking the E
protein are attenuated in vivo (23).
The membrane (M) protein is an abundant small protein
that is essential for virion assembly (170). Recently, a SARS-
CoV M mutation that confers efficient dissemination and in-
creased replication in primary human kidney cells, presumably
by interactions with key cellular targets that efficiently enhance
the assembly and release of infectious virions, has been iden-
tified (91). Unfortunately, the mechanism by which these mu-
tations enhance virion yields and/or infectivity is unknown. The
nucleocapsid protein is an internal virion protein that binds to
and packages the viral RNA into the virion (39). The N protein
is also tightly associated with replication complexes and may
function as a chaperone protein to regulate efficient sub-
genomic mRNA synthesis (171).
The viral and cellular components of the virion proteome
are the subject of some controversy. A comprehensive pro-
teomic approach was undertaken by Neuman et al. using a
mass spectrophoretic analysis of purified virions (86). This com-
prehensive approach demonstrated that ORF6 and ORF7a were
not localized in purified SARS-CoV virions, challenging pre-
vious reports in the literature (48, 49). Surprisingly, the repli-
case proteins NSP2, NSP3, and NSP5 and group-specific pro-
teins ORF3b and ORF9b were found abundantly in the
purified virions (86). Among these, NSP2, ORF3b, and ORF9b
are nonessential and can be deleted from the genome without
seriously affecting replication efficiency in vitro (40, 162). Im-
portantly, NSP3 and NSP5 encode proteolytic activities that
process the ORF1a/b polyprotein into individual replicase
components and potentially process a variety of cellular pro-
teins as well (170). At this time, the precise location and func-
tion of these proteins in the virion are unclear and under
investigation. Additionally, many host cellular proteins were
identified in the virion, including many ribosomal, nuclear,
endoplasmic reticulum (ER), Golgi apparatus, and plasma
membrane proteins. The reason for the disparity among these
three studies is unknown but may represent differences in the
stringency of virion preparation or may be due to differences in
the culturing conditions. One complication is that SARS-CoV
produces noninfectious particles as well as fully functional viri-
ons, potentially confounding interpretations of data from mass
spectrophoretic versus immunoelectron microscopy studies.
Continued work using antibodies to each identified protein in
virions will be necessary to determine viral and cellular pro-
teome participation in virion assembly, maturation, and infec-
tivity. The role of this plethora of host proteins in coronavirus
virion formation, function, infection, and pathogenesis remains
unknown but might help virions escape immune recognition.
Nucleocapsid Protein
The SARS-CoV and MHV nucleocapsid proteins have been
shown to affect different aspects of the innate immune re-
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sponse and appear to modulate several signaling pathways in
the cell. Many of these studies were performed using overex-
pression constructs in isolation and have not been confirmed in
the context of virus infection. He et al. showed that N is able to
induce AP-1 signaling in vitro (44). Kopecky-Bromberg et al.
showed that SARS-CoV N was able to block the induction of
reporter gene expression from an IFN-
 promoter and also
block NF-B signaling (59). They indicated that the N protein
is also able to inhibit an ISRE promoter in response to Sendai
virus infection but not IFN-
 treatment. The mechanism by
which this inhibition is occurring is unknown and under inves-
tigation. When expressed in a chimeric vaccinia virus, the
MHV N protein was also shown to inhibit the activation of
PKR, a strongly antiviral protein, in the cytoplasm (156). Ye et
al. further demonstrated that type I IFN was not induced and
that PKR was not activated in MHV-infected cells (156). PKR
activation normally leads to a block in protein synthesis by
phosphorylating the alpha subunit of the translation factor
eIF2. While N does not itself prevent PKR activation, it alters
PKR’s function such that it no longer signals properly. The N
proteins between these two group 2 coronaviruses are quite
conserved, so it will be interesting to determine if they both
encode overlapping functions during infection or whether
there really are distinct inhibitory mechanisms.
Of note, the various domains of coronavirus nucleocapsid
may affect many pathways similar to that of influenza virus
NS1. Both proteins have RNA binding and protein-protein
interaction domains that may be important for their host cell
functions. NS1 has been shown to affect mRNA nuclear export,
mRNA stability, IRF3 activation, and STAT1 and NF-B sig-
naling (14, 60, 61, 82, 101, 102, 164). Various domains of NS1
affect each pathway differently but together produce a multi-
layered modulation of various host signaling pathways. Thus,
each domain of nucleocapsid may be performing multiple
functions on multiple pathways during infection as well. The
MHV nucleocapsid protein has also been shown to have a role
in the induction of viral hepatitis (89). Ning et al. showed that
the nucleocapsid from MHV type 3 induces fgl2 prothrom-
binase to induce fibrin deposition and fulminant liver failure
(89). This leads to the hypothesis that nucleocapsids from
other coronaviruses may encode IFN antagonism and signal
transduction-modulating activities that are yet to be uncov-
ered.
Many questions remain concerning the role of the N protein
in replication and pathogenesis. Will each coronavirus nucleo-
capsid gene encode activities similar to those described here or
encode distinct activities that target other pathways in the cell?
Each coronavirus also targets and infects different cell types
and organs. Consequently, N protein functions may play dif-
ferent roles in pathogenesis in different cell types and species.
SARS-CoV infects primarily ciliated airway cells and type II
pneumocytes, while MHV infects neurons, glia, and liver cells,
depending on the strain. Is this difference correlated with dif-
ferent evolving functions of N in disease? Since N can be
differentially phosphorylated on many sites in the protein, it is
possible that different N isomers/posttranslational modifica-
tions function differently to potentiate disease outcomes? We
believe that the current molecular virology and reverse genetic
platforms provide an approach to elucidate the complex virus-
host interactions that lead to disease.
Accessory Proteins
Each coronavirus genome encodes a distinct set of accessory
proteins that are somehow important in the virus life cycle.
SARS-CoV encodes ORFs 3a, 3b, 6, 7a, 7b, 8, and 9b and an
ORF internal to N (31). MHV encodes ORFs 2a, 4, and 5a.
There is no overlap or homology among these proteins across
these two strains. To date, the only coronavirus accessory pro-
teins shown to antagonize IFN pathways are derived from
SARS-CoV (34, 59). In work described previously by Kopecky-
Bromberg et al., ORF3b and ORF6 were shown to block IFN
induction and IFN signaling. While the mechanism for ORF3b
antagonism has not been identified, the mechanism by which
ORF6 antagonizes host innate immune signaling has been
clearly elucidated. Studies from our group and others (34, 59,
131) have shown how ORF6 blocks the IFN signaling arm of
the innate immune response.
ORF6 is a 63-amino-acid ER/Golgi membrane protein that
has its C-terminal tail facing the cytoplasm and its N terminus
either in the ER lumen or associated with the ER membrane.
We found that ORF6 was able to block the nuclear import of
the STAT1/STAT2/IRF9 and STAT1/STAT1 complexes in the
presence of IFN-
 or IFN- treatment, respectively (34).
ORF6 expression resulted in the reduction of STAT1-depen-
dent gene induction. The C-terminal 10 amino acids were
critical for this import block, mediated by a recruitment of
nuclear import factors to the ER/Golgi membrane (Fig. 3).
Using a variety of approaches, we found that KPNA2 was
specifically bound to the C-terminal tail of ORF6. This re-
tained KPNA2 at the ER/Golgi membrane and, subsequently,
recruited KPNB1 to the ER/Golgi membrane as well. The
recruitment of KPNB1 onto membrane complexes limited the
bioavailability of KPNB1, an essential component that was
needed for the nuclear import of STAT1 complexes. Conse-
quently, ORF6 blocked the nuclear import of the STAT1 com-
plexes. ORF6 may affect other signaling pathways since
KPNB1 is a common component of the classical nuclear im-
port pathways. ORF6 has also been shown to increase the
pathogenesis of the normally nonlethal MHV-A59 virus (96).
In vitro studies with the MHV/ORF6 virus showed that ORF6
expression increased the level of virus production from cells
compared to the level of expression of wild-type (WT) virus.
Recently, Hussain et al. showed that ORF6 expression is able
to block proteins containing classical import signals but not
proteins that use nonimportin nuclear import mechanisms, in
agreement with our work showing that ORF6 blocks KPNB1-
mediated nuclear import (50). MHV’s accessory proteins have
not been implicated in impacting the innate immune response;
however, they may play a role in MHV’s capacity to evade the
innate immunosensing proteins, as the deletion of some but
not all of these proteins impacts in vivo pathogenesis (24).
The clear association of SARS-CoV ORF6 and Ebola virus
VP24 with the host nuclear import pathway identifies it as a
key site of virus-host interactions that modulate and regulate
the intracellular environment. By modulating the kinetics of
nuclear import during infection, the virus controls innate im-
mune, adaptive immune, apoptotic, and cell stress signaling
networks. While the mechanism may vary, it would be surpris-
ing if other pathogenic viruses do not modulate the same
pathways as those seen in SARS-CoV during their infection
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process. The levels of karyopherin proteins vary by cell type
and age of the cells as well, so the effect of ORF6 in cells may
depend on the amount of import factors available for binding
and inhibition (99, 154).
Replicase Proteins
The 5-end 20 kb of each coronavirus genome consists of
two large, overlapping ORFs, which encode 15 to 16 proteins
that are localized in replication complexes and are thought to
function primarily in regulating viral replication and transcrip-
tion in infected cells. About 13 kb from the 5 end, a ribo-
somal frameshifting site is encoded, which allows the efficient
translation of the downstream ORF1b, encoding replicase, he-
licase, and a variety of novel RNA-processing enzymes whose
exact function in coronavirus transcription is unclear. Once
translated, the polyprotein produced from ORF1a or ORF1a/b
is processed by virally encoded proteases, the papain like-pro-
tease (PLP) encoded in NSP3 and the main protease (Mpro)
encoded by NSP5. Each protease cleaves the polyprotein at spe-
cific sites to liberate the 16 polyproteins used in SARS-CoV
replication (reviewed in references 9 and 79). It has been postu-
lated that the intermediate versions of the cleaved polyprotein
may also have some special functions, although direct support for
this hypothesis has recently been challenged in the literature (28,
29, 116).
Although there is significant homology between the repli-
case proteins (or nonstructural proteins [NSPs]) of coronavi-
ruses, in general, the replicase proteins nsp1 to nsp3 at the 5
end of the genome are most heterogeneous (74). In contrast,
nsp7 to nsp10 are highly conserved among coronaviruses. Dif-
ferent coronavirus family members also encode different num-
bers of functional PLPs. For example, SARS-CoV encodes a
single PLP, while MHV encodes two PLPs in NSP3. In the
latter, both PLPs are active and preferentially target different
cleavage sites to liberate nsp1 to nsp3 from the ORF1a
polyprotein. Most NSPs are essential for replication, although
in SARS-CoV and MHV, NSP2 is nonessential, portions of
NSP1 have also been deleted, and various mutations have been
made in other replicase proteins (for example, NSP15) (41).
NSP1
Historically, the replicase proteins were thought to function
exclusively in RNA synthesis, influencing viral disease out-
comes as a function of virus load. The finding that several
coronavirus replicase proteins function in innate immune eva-
sion was surprising. This observation changes the old paradigm
by directly implicating replicase protein function in pathogen-
esis and virulence. Structurally, SARS-CoV NSP1 is a 20-kDa
protein that is localized in the cytoplasm of infected cells (20).
While all coronaviruses encode an NSP1-like protein, SARS-
CoV NSP1 may encode a variety of unique functions. Using
overexpression plasmids, both NSP1 and NSP3 have been
shown to encode innate immune antagonism activities. Kami-
tani et al. and Narayanan et al. demonstrated that NSP1 was
able to block IFN-
 mRNA induction but did not antagonize
the IRF3 signaling pathway (56, 84). NSP1 expression de-
graded not only IFN-
 mRNA but also several endogenous
cellular mRNAs as well. As SARS-CoV-infected cells also
degraded cellular mRNA, those authors proposed that the
nsp1 degradation of host mRNA is an important mechanism of
blocking host antiviral defenses. In a recent paper by Naray-
anan et al., they described an NSP1 mutant virus that loses its
ability to degrade host mRNA and, interestingly, that induces
a large amount of IFN-
 during infection (84).
Other work suggested that SARS-CoV NSP1 can directly
antagonize IFN induction. Wathelet et al. demonstrated that
NSP1 inhibits the signal transduction pathways involving IRF3,
STAT1, and NF-B (144). They showed that NSP1 is able to
block STAT1 phosphorylation and IRF3 dimerization and af-
fects cell cycle progression without inducing apoptosis. Using
an NSP1 mutant, those authors showed that the recombinant
virus was more sensitive to IFN treatment, agreeing with the
previously published work showing that NSP1 is an IFN an-
tagonist. Interestingly, those authors did not observe the
mRNA degradation phenotype seen in the previous studies,
suggesting that additional work is needed to delineate the
exact role of NSP1 as an innate immune antagonist and its
potential role in selective host mRNA degradation.
Recent work by Zust et al. also showed that NSP1 in MHV
affects virus survival in vivo (172). They found that the deletion
of the first 99 amino acids of NSP1 in MHV produced a virus
that grew efficiently in tissue culture but did not grow well in
mice. In fact, 100% of the WT virus-infected mice died, while
the mutant virus-infected mice all survived. IFN induction in
the NSP1 mutant-infected macrophages was increased com-
pared to that in WT virus-infected macrophages. Those au-
thors showed that in type I IFN receptor knockout mice, the
nsp1 mutant virus replicates to WT levels. These data suggest
a role for NSP1 in MHV pathogenesis in mice; however, its
exact mechanism of action is unknown.
NSP3
SARS-CoV NSP3 is one of the larger cleaved products of
ORF1a in the SARS-CoV genome, encoding a multifunctional
200-kDa protein that includes several predicted glycosylation
sites. Several different functional domains of NSP3 have been
identified, including a poly(ADP-ribose) binding domain, pro-
tease, deubiquitinase, and de-ISGylase. Wathelet et al. also
demonstrated that the overexpression of NSP3 antagonized
host IFN responses as well (144). Using a luciferase-based
screen, Wathelet et al. showed that SARS-CoV NSP3 expres-
sion blocked IFN-
 induction after cells were infected with
Sendai virus. This investigation did not, however, identify
which domain(s) of NSP3 was responsible for that block. In
support of these findings, Devaraj et al. showed that the SARS-
CoV PLP domain of NSP3 was responsible for the antagonism
of the IFN-
 response (27). Using transfection experiments
with only the PLP domain, those authors demonstrated that
PLP blocked IFN-
 induction via Sendai virus infection and
poly(I:C) treatment by inhibiting phosphorylation, dimeriza-
tion, and nuclear import of IRF3. Furthermore, those authors
showed that PLP and IRF3 coprecipitated and that the inter-
action was independent from the enzymatic function of PLP.
Mutations in the active site of the protease that blocked PLP
activity did not affect IRF3 binding.
Recent unpublished work from our laboratory suggests that
while PLP is an IFN antagonist, the mechanism of action is
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different than what was described previously by Devaraj et al.
We find that PLP is able to inhibit IRF3-mediated IFN induc-
tion and block IRF3 phosphorylation; however, we also find
that PLP is able to inhibit NF-B gene induction (M. Frieman
et al., unpublished data). Devaraj et al. showed that PLP had
no effect on the NF-B pathway (27). While PLP blocks IRF3
phosphorylation, it increases the phosphorylation of IB, the
inhibitor of NF-B activation. We also find that identical cleav-
age site mutants used in the study reported Devaraj et al.
produce various degrees of IFN and NF-B inhibition in our
assays, with some mutants maintaining the IFN antagonist
activity and others losing their antagonist activity. Interest-
ingly, we can show that the ubiquitin-like domain at the N
terminus of PLP is a determinant of IFN antagonist function.
The deletion of the ubiquitin-like domain from PLP leads to a
loss of IFN-antagonistic activity for both IRF3 and NF-B
pathways; however, the protease remains active. We are cur-
rently identifying the mechanism of action of PLP in vitro and
in vivo.
Cell Types Involved in the SARS-CoV Interferon Response
During the initial infection with SARS-CoV, two large
groups of cell types figure prominently in the innate immune
response. SARS-CoV utilizes the ACE2 protein on the surface
of epithelial cells as its cellular receptor, and its expression is
essential for virus entry (69). Cell types that are prominent
targets for SARS-CoV infection include bronchiolar epithelial
cells, especially ciliated epithelial cells and alveolar type II
pneumocytes. A second broad class of important contributors
to pathogenesis includes the infiltrating immune cells that are
composed primarily of macrophages, neutrophils, and DCs.
DCs can be further divided into myeloid-type DCs (mDCs)
and pDCs, both of which have been shown to be important in
clearing viral infections (1, 53, 83). When activated, pDCs
produce large amounts of type I IFN to signal neighboring cells
of the incoming infection. mDCs do not produce type I IFN to
the extent of pDCs but are important in the acquired immune
response by secreting chemokines necessary for the activation
of B cells and T cells.
SARS-CoV has also been shown to use DC-SIGN and L-
SIGN as coreceptors for entry (54, 78). Each one is abundantly
expressed in DC populations, and coronavirus infection of DCs
in culture shows an interesting interaction between virus and
cell. In pDCs, SARS-CoV and MHV did not progress to a
productive infection and did not produce progeny viruses;
however, incubating pDCs with virus induced the production
of large amounts of type I IFN (12). Although SARS-CoV
infection was not analyzed, MHV was shown to signal through
TLR7 and MyD88, which were essential for IFN-
 expression
(12). TLR7, a membrane protein localized primarily in endo-
somes, may function as a crucial sentinel for the detection of
coronavirus infection. TLR7 signals through IRF7 to induce
IFN-
 expression. In the absence of intracellular infection and
gene expression, it is unlikely that the IFN antagonist proteins
will be produced in quantities that would block IFN signaling
or expression, although nsp3, the N protein, and perhaps
ORF6 may be present in sufficient quantities with the virion to
provide low-level antagonism. Importantly, pDC depletion
with antibodies prior to MHV infection diminished the quan-
tity of IFN produced during infection and resulted in increased
viral replication and disease. These data demonstrated that the
initial sensing of coronaviruses by the innate immune machin-
ery might be the critical step in protecting the host from in-
fection.
AGING AND PATHOGENESIS
The impact of host senescence on viral pathogenesis is be-
ginning to be understood at the molecular level. In the case of
influenza virus, the rates of hospitalizations of people under 5
and over 65 years of age are essentially the same, although
importantly, those over 65 years of age are 35 times more likely
to die from infection (21). During the SARS-CoV epidemic,
the elderly were more likely to die from SARS-CoV infection
than any other age group (13, 71). The elderly exhibit a de-
crease in their adaptive immune response with increasing age,
which parallels their increase in morbidity and mortality after
infection (64). Studies of the responsiveness of the innate im-
mune response in the elderly are limited and have shown
conflicting results. In an aged mouse infection with coxsack-
ievirus B3 and Newcastle disease virus, the levels of IFN- and
-
 were decreased in aged mice compared to those in young
mice (113). The results with poly(I:C) treatment, a potent type
I IFN inducer, in old mice have demonstrated either a decrease
or an increase in IFN production (55, 166). A better under-
standing of the relationship between aging and both the innate
and adaptive immune responses is necessary to understand the
increased pathogenesis of SARS-CoV in the elderly popula-
tion.
While investigating the aging phenomenon in SARS-CoV
susceptibility, we have begun to identify how aged mice re-
spond to SARS-CoV vaccines. We have shown that SARS-
CoV vaccine efficacy wanes in aged mice when mice were both
vaccinated when young and challenged when old. More impor-
tantly, vaccinated aged animals mounted extremely poor im-
mune responses and were not protected from challenge with a
homologous virus (26). Additionally, aged mice are more sus-
ceptible to SARS-CoV infection and produced more lung
damage and pathology than young mice (106). The reasons for
the increased pathogenesis of SARS-CoV in aged animals re-
mains to be elucidated but reflects a more global issue of
understanding the molecular mechanisms of disease and re-
versing disproportionate disease burdens that are noted in the
elderly after many viral infections. Current work on identifying
susceptibility alleles specific to aged individuals compared to
young individuals may aid in our understanding of the increase
in infectivity and pathogenesis in the elderly.
CONCLUSION
Coronaviruses have emerged as an important model system
to study virus-host interactions. Their large genomic RNA
encodes a variety of novel proteins, many of which have solved
structures containing novel protein folds but only predicted
functions in virus replication and pathogenesis. The tools of
molecular virology, robust sequence databases of human and
animal strains, well-characterized mouse models of severe end-
stage lung disease, age-related susceptibility phenotypes, and
the ability to develop systems biology and genetic approaches
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will allow a detailed understanding of coronavirus pathogene-
sis and emergence. This will make it a choice model for illu-
minating novel virus-host interactions that regulate severe dis-
ease outcomes in young and immunosenescent animals and
humans.
The molecular biology tools of reverse genetics allow the
unprecedented genetic interrogation of the large RNA virus
genome. Infectious clones for SARS-CoV, bat SARS-CoV,
MHV, transmissible gastroenteritis virus, infectious bronchitis
virus, and human coronaviruses OC43, NL63, and 229E will
enable the research community to manipulate these genomes
and identify the role of each protein in virus-host interactions,
pathogenesis, and disease (10, 26, 95, 110, 134, 158–161).
Despite the identification of several innate immune antagonist
genes in the Coronaviridae genome, the role of these genes in
regulating disease outcomes and pathogenesis remains an im-
portant focus for future investigations. Although it is well rec-
ognized that changes within the S glycoprotein regulate the
initial steps in cross-species transmission via receptor interac-
tions, adaptation and virulence determinants are generally
poorly understood.
SARS-CoV emergence was associated with a large number
of adaptive changes within nsp3, nsp4, nsp9, NSP14, NSP15, S,
M, ORF3a, E, N, and ORF8, which may influence disease
outcomes (15). It is not clear whether innate coronavirus an-
tagonism genes play a key role in adaptation and transmission
to new host species as has been described for poxviruses (142).
Surprisingly, SARS-CoV and the less virulent human corona-
virus NL63 both utilize the same receptor, ACE2, for docking
and entry into cells, yet NL63 is significantly less pathogenic
than the SARS-CoV (47). These data suggest that novel func-
tions are encoded within the SARS-CoV genome to enhance
virulence. Do the novel accessory ORF functions encoded
within the highly pathogenic SARS-CoV represent the key
ingredients to high virulence? Equally important is the notion
that the replicase proteins encoded within ORF1a and ORF1b
are multifunctional, regulating replication efficiency while en-
gaging select host cell signaling machinery to promote an in-
tracellular environment conducive to virus growth and patho-
genesis. Given the availability of novel tools, multiple novel
proteins, robust genetic systems, and reagents, coronaviruses
provide a novel opportunity to investigate interesting interac-
tions between host cells and viral pathogens.
Future Directions
Comparison of these different systems necessitates a holistic
view of disease processes. While we may start at the level of
what happens in a tissue culture flask, it is the intimate inter-
actions between the infected cell and its neighbors that deter-
mine the course of disease. The secretion of cytokines and
chemokines from infected tissue and the subsequent recruit-
ment of macrophages, DCs, neutrophils, and eosinophils will
be critically important for the survival of the host. How each
virus modulates this response may very well represent the
distinguishing features between a lethal or mild, acute or
chronic, highly pathogenic virus infection.
Systems Biology
Use of a systems biology approach may enable us to finally
understand the intricate dynamics between the cell and virus
proteome that eventually constitute a particular disease phe-
notype. By comparing the transcriptional profiles of a lung
epithelial cell during the course of infection with SARS-CoV,
influenza virus, Ebola virus, human coronavirus NL63, or
respiratory syncytial virus may allow an understanding of the
pathways and proteins that are involved in the host response.
The integration of transcriptome data, proteomic profiles, and
detailed interaction networks between viral and cellular pro-
teins should provide a systems view of the intricate communi-
cation networks regulating virus infection at the cellular level.
Platform approaches for each of these key system components
are available, providing high-throughput identification of the
interaction networks and the impact on host expression (re-
viewed in reference 130). Additionally, lipidomic and metabo-
lomic profiles may be useful in adding more data to our un-
derstanding of the infection. Comparing the responses to
infection in lungs from SARS-CoV-, H5N1 influenza virus-,
Ebola virus-, and respiratory syncytial virus-infected hosts can
further our understanding of how the each virus modulates the
innate immune response.
Animal Models and Systems Genetics
The obvious limitation to all of these studies is the animal
model system. For SARS-CoV, a mouse-adapted virus repro-
duces the acute disease progression found in the more severe
cases of SARS-CoV infection in humans (106). Moreover,
animal models that reproduce the complex age-related pheno-
type and that progress to acute respiratory distress syndrome
provide novel resources for illuminating pathogenic mecha-
nisms in vivo (110). In the various SARS-CoV models, the
genetic background of the mouse heavily influences pathogenic
outcomes. The role of host susceptibility alleles in coronavirus
pathogenesis, as well as most viral pathogens, is heavily under-
studied and represents a major target for future research.
Mouse resources that allow an understanding of the roles of
polygenic traits in viral pathogenesis are now becoming avail-
able, like the Collaborative Cross mice (109). Using these
mouse resources, detailed systems genetic approaches can be
developed to understand the mechanisms by which host sus-
ceptibility alleles interact with the virus proteome to potentiate
different disease outcomes.
The use of a systems genetic approach may be our best
chance at identifying the host genes responsible for coronavi-
rus disease and age-related susceptibility phenotypes. The abil-
ity to manipulate both the viral and host genetic systems will
allow a further understanding of the parameters of pathogen-
esis and virus control for both mouse and human disease. With
the power of systems biology and genetics, an intricate under-
standing of the elegant interplay between a pathogen and its
host should result in novel targets for antiviral drugs and ther-
apies in the future.
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